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Background
P r o t e i np r o d u c t i o ni nC H Oc e l ll i n e si sah i g h l y
dynamic process, where the yield limiting step can shift
among transcription, translation, and secretion under
different cell growth stages and culture conditions. In
addition, the choice of CHO cell line has been shown to
affect target protein quality and quantity.
Further advancements in titer and specific productivity
require elimination of cellular/process bottlenecks along
the generation of stable production cell lines including
vector design, clone selection, genetic engineering, and
media and feed optimization.
To overcome these limitations, we developed a tool-
box for all process phases from transfection to produc-
tion. This toolbox is based on a chemically defined
media platform and includes pre-adapted CHO-K1 or
CHO-DG44 cell lines, optimized vectors for single and
multi-chain proteins as well as fine-tuned protocols. In
addition, it enables the production of antibodies with
specialized glycan structures (GlymaxX
® [1]) as well as
clone engineering with regard to the expression and
secretion machinery (CDC42).
Materials and methods
ProBioGen‘s toolbox expression vectors encoding an Fc-
protein or therapeutic glycoprotein were generated
using gene-optimized sequences and optimized signal
peptides.
To create stable cell lines, expression vectors were
transfected into CHO-DG44 and CHO-K1 cells by
microporation. Two serum-free selection strategies were
applied using both MTX and puromycin: selection in
semi-solid medium followed by automated clone picking
and deposition into 96 wells using the ClonePix FL
(Genetix), and combined selection and cloning in 96-
well plates. For a first expression analysis monoclonal
primary clones were subjected to 96-well plate assay.
Clones showing best performance in 96-well were
expanded and taken into batch and fed-batch for pro-
ductivity assessment. Best performing primary clones
were subjected to a second cloning step by limiting dilu-
tion and analyzed in 96-well. Following clone scale-up
highest ranking sub-clones clones were assessed in
shake flask using fed-batch. Prior to master cell banking
candidate lead clones were tested for fed-batch bioreac-
tor performance in a Cellferm-pro
® (DASGIP AG). Pro-
tein concentrations were determined using either an
ELISA method, the Gyrolab SIA Ligand Binding Assay
or an HPLC method.
Protein secreted from stable cell lines was purified
either by protein A affinity chromatography (Fc-protein)
or Ion Exchange Chromatography using weak anion
exchangers (glycoprotein) and evaluated by Size-Exclu-
sion HPLC (SEC), Western blot and SDS-PAGE.
To determine the stability of clones a continuous pas-
sage of roughly 80 population doublings with analyzing
protein batch titers as well as mRNA levels and gene
copy numbers (StepOnePlus™ RT-PCR System) at
defined time points was performed. Cells were cultivated
without selection pressure.
Results and conclusion
Here we describe an innovative parallel platform cell
line development for CHO-K1 and CHO-DG44 (Figure
1) exemplified by two completely different recombinant
proteins, an Fc-protein and a therapeutic glycoprotein,
with the glycoprotein showing differences in glycosyla-
tion pattern in the two starter cell lines.
Our toolbox approach enables a fast and highly repro-
ducible generation of high producer clones stably
expressing the transgene for more than 80 generations
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yields of 4.5-13 g/L (Table 1).
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Figure 1 Overview of PBG Cell Line Development
Table 1 Growth and protein production data of CHO producer clones in different assay formats
Fc-protein Glycoprotein
Assay format Cell line Max VCD [viable cells/mL] Max Titer [mg/L] Max VCD [viable cells/mL] Max Titer [mg/L]
96-well plate assay K1 nd
a 50 nd
a 268
(5 days) DG44 nd
a 176 nd
a 607
Batch K1 2.3E+07 610 1.1E+07 1772
(5 or 7 days) DG44 8.6E+06 980 6.4E+06 2200
Fed batch K1 3.0E+07 2500 1.9E+07 8100
(12-17 days) DG44 1.7E+07 4500 3.0E+07 13200
a not determined
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